

BIOEQUITYEUROPE.COM

MAY KURSAAL ELKARGUNEA CENTER
12-14 **SAN SEBASTIÁN, SPAIN**

MAY **VIRTUAL**
21-22 **1x1 MEETINGS**

ORGANIZED BY **BIOCENTURY** **EBD**
GROUP

24. BIO€QUITY
EUROPE



RISE ABOVE THE NOISE

This year we will gather in San Sebastián, Spain, Basque Country, to discuss how biotechs can rise above the noise to attract the right investors, partners, and talent.

- Debate how to stand out from the crowd and reach the discussion stage with investors and pharma.
- Meet VCs, CEOs, and BD&L leaders in an intimate setting designed for networking and discussion.
- Discover 100+ emerging biotechs selected for the Presenting, Next Wave and Pre-Seed Company Tracks.
- Dive into European biotech trends with an exclusive conference report from Insights Partner McKinsey & Company.
- Schedule one-to-one meetings; check out the Poster Session; take your conversation outside, onto the beach.

ORGANIZED BY

BIOCENTURY **EBD** GROUP

FOUNDING SPONSOR

Sofinnova
partners

INSIGHTS PARTNER

McKinsey
& Company

REGIONAL HOST COMMITTEE



Gipuzkoako
Foru Aldundia
Diputación Foral
de Gipuzkoa

YSIOS CAPITAL

THE BIO€QUITY EUROPE EXPERIENCE

The industry's premier CEO & investor conference

Where decision-makers gather to network, partner, and debate critical issues facing the biotech industry

Showcasing strategies to succeed in Europe, and for Europe to succeed on the global stage – from capital, to talent, to product and business development, and more

300+ biotech CEOs, 300+ VCs, 150+ CFO/COO/CBOs

2+ DAYS

Of strategic panels and keynotes tailored for C-Suite executives

100+

Presenting companies from Europe, the U.S. and Asia, hand-picked by BioCentury

1x1

Schedule meetings through EBD's partneringONE system

VIP

Peer-to-peer networking

EXCLUSIVE REPORT

McKinsey returns to deliver its 5th conference report on Europe's biotech ecosystem

"BioEquity Europe is a 'must go' for both VCs and CEOs of life science companies in Europe ... it is the event where you can feel the pulse of the industry ..."

Antoine Papiernik
Chairman & Managing Partner
Sofinnova Partners

"BioEquity brings together top stakeholders in the life sciences European VC space. The event stands out by delivering quality thought leadership. For the biotech VC community, this is Europe's flagship event."

Nanna Lüneborg, Ph.D.
General Partner
Forbion

"BioEquity Europe is a great meeting for strategic discussions about access to capital and talent. It's also a key networking event for investors and biopharma executives in Europe."

Paul Peter Tak, M.D., Ph.D.
President & CEO
Candel Therapeutics

"BioEquity is the leading event for the biotech industry in Europe.... It brings all actors together and creates an atmosphere and platform for true networking and business development."

Jorge Santos da Silva, Ph.D.
CEO
MoonLake Immunotherapeutics

"BioEquity is the premier life sciences forum in Europe connecting industry leaders, emerging life science companies, and members of the investment community. The content it delivers is unmatched and makes it a priority event for any decision maker in our industry."

Christoph Broja
Managing Director
EQT Life Sciences



BIO€QUITY PRESENTING COMPANY CLASS OF 2024

Preliminary Schedule Subject to Change; Revised on May 10, 2024

TRACK		DATE	TIME	ROOM
AUTOIMMUNE, INFLAMMATION AND FIBROSIS	FULL PRESENTERS	MAY 14	10:30 - 11:27	ROOM 9
CANCER	FULL PRESENTERS	MAY 13	10:00 - 12:57	ROOM 4+5
	FULL PRESENTERS	MAY 14	09:00 - 11:42	ROOM 6+7
	NEXT WAVE PRESENTERS	MAY 13	14:50 - 17:19	ROOM 9
CARDIOVASCULAR AND HEMATOLOGY	FULL PRESENTERS	MAY 14	11:45 - 12:27	ROOM 6+7
CELL AND GENE THERAPY MANUFACTURING	FULL PRESENTERS	MAY 13	14:00 - 14:42	ROOM 4+5
CELL AND GENE THERAPY	FULL PRESENTERS	MAY 13	14:45 - 17:57	ROOM 4+5
	NEXT WAVE PRESENTERS	MAY 14	10:00 - 11:59	ROOM 4+5
ENDOCRINE AND METABOLIC	FULL PRESENTERS	MAY 13	11:15 - 12:57	ROOM 6+7
	NEXT WAVE PRESENTERS	MAY 13	11:50 - 12:09	ROOM 9
INFLAMMATION AND FIBROSIS	NEXT WAVE PRESENTERS	MAY 13	11:10 - 11:49	ROOM 9
INFECTIOUS DISEASES AND VACCINES	FULL PRESENTERS	MAY 14	09:00 - 09:57	ROOM 9
	NEXT WAVE PRESENTERS	MAY 13	12:10 - 12:59	ROOM 9
MICROBIOME THERAPEUTICS	FULL PRESENTERS	MAY 14	11:30 - 12:12	ROOM 9
NEUROLOGY	FULL PRESENTERS	MAY 13	14:00 - 16:42	ROOM 6+7
	NEXT WAVE PRESENTERS	MAY 14	12:00 - 14:09	ROOM 4+5
NUCLEIC ACID THERAPEUTICS	FULL PRESENTERS	MAY 13	10:00 - 10:57	ROOM 6+7
	NEXT WAVE PRESENTERS	MAY 13	14:00 - 14:49	ROOM 9
RENAL	FULL PRESENTERS	MAY 14	10:00 - 10:27	ROOM 9
TECHBIO AND AI-GUIDED DISCOVERY	FULL PRESENTERS	MAY 13	16:45 - 17:42	ROOM 6+7
	NEXT WAVE PRESENTERS	MAY 13	10:00 - 11:09	ROOM 9
HOT TOPICS	FULL PRESENTERS	MAY 13	11:00 - 11:12	ROOM 6+7
		MAY 13	17:45 - 17:57	ROOM 6+7
		MAY 14	12:15 - 12:27	ROOM 9
	NEXT WAVE PRESENTERS	MAY 14	13:30 - 14:57	ROOM 6+7
		MAY 13	17:20 - 17:59	ROOM 9
		MAY 14	13:30 - 14:29	ROOM 9
		MAY 14	14:10 - 14:59	ROOM 4+5

Full Presenters are typically more mature, and are further in the clinic or have raised more capital



BIO€QUITY PRESENTING COMPANY CLASS OF 2024

MONDAY, MAY 13

ROOM 4+5

FULL PRESENTERS	
CANCER	
10:00	Abalos Therapeutics GmbH
10:15	Sibylla Biotech S.p.A.
10:30	Alentis Therapeutics AG
10:45	Step Pharma S.A.S.
11:00	Bantam Pharmaceutical LLC
11:15	Tubulis GmbH
11:30	Biolnvent International AB
11:45	Domain Therapeutics S.A.
12:00	Egle Therapeutics S.A.S.
12:15	Enterome S.A.
12:30	Epsilon Ltd.
12:45	Ariceum Therapeutics GmbH
CELL AND GENE THERAPY MANUFACTURING	
14:00	Adva Biotechnology Ltd.
14:15	Viralgen Vector Core S.L.
14:30	* Jiangsu Hillgene BioPharma Co. Ltd.
CELL AND GENE THERAPY	
14:45	* bit.bio
15:00	* AlveoGene Ltd.
15:15	Amarna Therapeutics B.V.
15:30	Alia Therapeutics s.r.l.
15:45	* SpliceBio S.L.
16:00	DiNAQOR AG
16:15	Luminary Therapeutics Inc.
16:30	Resolution Therapeutics Ltd.
16:45	* SonoThera Inc.
17:00	Coave Therapeutics S.A.
17:15	* Vivet Therapeutics S.A.S.
17:30	* ImmunoScape Pte. Ltd.
17:45	TreeFrog Therapeutics

ROOM 6+7

FULL PRESENTERS	
NUCLEIC ACID THERAPEUTICS	
10:00	Arthex Biotech S.L.
10:15	Ethris GmbH
10:30	Ziphius Vaccines N.V.
10:45	* Kernal Biologics Inc.
HOT TOPICS	
11:00	MRM Health N.V.
ENDOCRINE AND METABOLIC	
11:15	Abliva AB
11:30	Arecor Therapeutics plc
11:45	Azafaros B.V.
12:00	Confo Therapeutics N.V.
12:15	OMass Therapeutics Ltd.
12:30	* Cytokine Pharma ApS
12:45	PK Med S.A.S.
NEUROLOGY	
14:00	Addex Therapeutics Ltd.
14:15	Araclon Biotech S.L.
14:30	Bioxodes S.A.
14:45	iN Therapeutics Co. Ltd.
15:00	Minoryx Therapeutics S.L.
15:15	Oryzon Genomics S.A.
15:30	Synendos Therapeutics AG
15:45	* Vesper Bio ApS
16:00	Akigai A/S
16:15	Noema Pharma AG
16:30	Stalicia S.A.
TECHBIO AND AI-GUIDED DISCOVERY	
16:45	Brainomix Ltd.
17:00	* Iktos S.A.S.
17:15	InSilicoTrials Technologies S.p.A.
17:30	Origenis GmbH
HOT TOPICS	
17:45	Acousia Therapeutics GmbH

ROOM 9

NEXT WAVE PRESENTERS	
TECHBIO AND AI-GUIDED DISCOVERY	
10:00	* BioCortex Ltd.
10:10	* Serna Bio
10:20	Evariste Ltd.
10:30	Enhanc3D Genomics Ltd.
10:40	* Aignostics GmbH
10:50	IMU Biosciences
11:00	Vilya Inc.
INFLAMMATION AND FIBROSIS	
11:10	* Focal Biosciences AG
11:20	* Kynos Therapeutics Ltd.
11:30	* Tribune Therapeutics AB
11:40	* Refoxy Pharmaceuticals GmbH
ENDOCRINE AND METABOLIC	
11:50	Pretzel Therapeutics Inc.
12:00	TECregen AG
INFECTIOUS DISEASES AND VACCINES	
12:10	* SurvivX B.V.
12:20	BiomeBank
12:30	* Obulytix s.r.l.
12:40	AstriVax N.V.
12:50	* Vesale Bioscience S.a.r.l.
NUCLEIC ACID THERAPEUTICS	
14:00	Flamingo Therapeutics Inc.
14:10	* Kudo Biotechnology Inc.
14:20	* Rnatics GmbH
14:30	Senisca Ltd.
14:40	NUAgo Therapeutics Inc.
CANCER	
14:50	* Oniria Therapeutics S.L.
15:00	Curve Therapeutics Ltd.
15:10	* Simmunext Biotherapeutics B.V.
15:20	* Tessellate Bio B.V.
15:30	* Cumulus Oncology Ltd.
15:40	* Traverse Biotech Inc.
15:50	FoRx Therapeutics AG
16:00	* Gate2Brain S.L.
16:10	Adiposs S.A.
16:20	Anavo Therapeutics B.V.
16:30	* Curadh MTR Inc.
16:40	* Infinitopes Ltd.
16:50	Commit Biologics ApS
17:00	WMT AG
17:10	Disco Pharmaceuticals GmbH
HOT TOPICS	
17:20	ACM Biolabs Pte. Ltd.
17:30	Cmr CureDiab Metabolic Research GmbH
17:40	Epoqe Pharma ApS
17:50	* Outrun Therapeutics Ltd.

* First-time Bio€quity Europe Presenters



BIO€QUITY PRESENTING COMPANY CLASS OF 2024

TUESDAY, MAY 14

ROOM 4+5

NEXT WAVE PRESENTERS

CELL AND GENE THERAPY

- 10:00 * Alder Therapeutics AB
- 10:10 * Bloomsbury Genetic Therapies Ltd.
- 10:20 SparingVision S.A.S.
- 10:30 EG 427 S.A.S.
- 10:40 * Laverock Therapeutics Ltd.
- 10:50 Pan Cancer T B.V.
- 11:00 StemSight Oy
- 11:10 Rinri Therapeutics Ltd.
- 11:20 Atamyo Therapeutics S.A.S.
- 11:30 Antion Biosciences S.A.
- 11:40 * CARTemis Therapeutics GmbH
- 11:50 * Ananda Immunotherapies Pte. Ltd.

NEUROLOGY

- 12:00 Zyvran Pharmaceutical Inc.
- 12:10 CaSRevolution s.r.l.
- 12:20 * TauC3 Biologics Ltd.
- 13:30 * MitoRx Therapeutics Ltd.
- 13:40 Muna Therapeutics
- 13:50 Golgi Neurosciences s.r.l.
- 14:00 * Sapient Therapeutics Ltd.

HOT TOPICS

- 14:10 * HAYA Therapeutics S.A.
- 14:20 * MultiOmic Health Ltd.
- 14:30 * Hawk Biosystems S.L.
- 14:40 * Plantibodies
- 14:50 * Actithera

ROOM 6+7

FULL PRESENTERS

CANCER

- 09:00 * Oncode Accelerator Foundation
- 09:15 * Oncomatrix Biopharma S.L.
- 09:30 * Biofidelity Ltd.
- 09:45 Montis Biosciences B.V.
- 10:00 * RS Oncology LLC
- 10:15 Storm Therapeutics Ltd.
- 10:30 PDC*line Pharma S.A.S.
- 10:45 * Feldan Therapeutics
- 11:00 Adcendo ApS
- 11:15 OncoOne Research & Development GmbH
- 11:30 * Tagworks Pharmaceuticals B.V.

CARDIOVASCULAR AND HEMATOLOGY

- 11:45 NanoPhoria s.r.l.
- 12:00 MiNA Therapeutics Ltd.
- 12:15 VarmX B.V.

HOT TOPICS

- 13:30 * Convert Pharmaceuticals S.A.
- 13:45 * Neurocentrx Pharma Ltd.
- 14:00 Rejuvenate Biomed N.V.
- 14:15 * DopaVision
- 14:30 * Allelica Inc.
- 14:45 iOmx Therapeutics AG

ROOM 9

FULL PRESENTERS

INFECTIOUS DISEASES AND VACCINES

- 09:00 * Glox Therapeutics Ltd.
- 09:15 ExeVir Bio B.V.
- 09:30 LimmaTech Biologics AG
- 09:45 Pneumagen Ltd.

RENAL

- 10:00 AM-Pharma B.V.
- 10:15 TES Pharma s.r.l.

AUTOIMMUNE, INFLAMMATION AND FIBROSIS

- 10:30 Fibrocor Therapeutics Inc.
- 10:45 GlycoEra AG
- 11:00 * Mabyon AG
- 11:15 MC2 Therapeutics A/S

MICROBIOME THERAPEUTICS

- 11:30 EnteroBiotix Ltd.
- 11:45 * Mikrobiomik Healthcare Company S.L.
- 12:00 Microviable Therapeutics S.L.

HOT TOPICS

- 12:15 Mestag Therapeutics Ltd.

NEXT WAVE PRESENTERS

HOT TOPICS

- 13:30 * OmicVision Biosciences ApS
- 13:40 * Cellvie AG
- 13:50 * Calissa Therapeutics
- 14:00 * Safenia Therapeutics Inc.
- 14:10 * Pheiron GmbH
- 14:20 Orion Biotechnology Canada Ltd.

* First-time Bio€quity Europe Presenters

PRE-EVENT NETWORKING EXCURSIONS

Build stronger connections with CEOs and investors by joining a pre-event networking excursion (Sunday, May 12, 2024). These excursions are expected to sell out.



Txakoli Winery Tour

Spanish Basque Country is famous for txakoli, a sparkling white wine. Join Bio€quity delegates for a tasting at a local txakoli winery followed by a networking lunch.

Chillida Leku Museum Tour

This year is the 100th birthday of Eduardo Chillida, one of the most influential Spanish artists of the 20th Century, and a native of San Sebastián. Join Bio€quity delegates on an exclusive guided tour by the Chillida family of the Chillida Leku outdoor sculpture museum followed by a networking lunch.

9-hole Golf Scramble

Join Bio€quity delegates for a nine-hole scramble at Goiburu golf course, located in the Leitzarán Valley in Basque Country, followed by a networking lunch.

Pintxos Walking Tour

San Sebastián is famous for its pintxos bars, a bucket list experience for foodies around the world. Join Bio€quity delegates on a guided walking tour of Old Town, where you will stop to sample pintxos from some of the town's most famous bars.


Hosted by:



**Space is limited and requires advance registration* [Click here to register your interest in joining](#)
Email conferences@biocentury.com for more information.*

ATTENDING ORGANIZATIONS

+ND Capital	Business Solutions	Anavo Therapeutics
30 Five Bio	Ahead Therapeutics	Andera Partners
3B Future Health Ventures	Aignostics	Angelini Ventures
4Bio Partners	Akigai	Ankrin Therapeutics
AATec Medical	Alder Therapeutics	Apaxen
AATS	Alentis Therapeutics	Apices Soluciones
Abalos Therapeutics	AlgoTherapeutix	Aplagon
AbbVie	Alia Therapeutics	Apollo Health Ventures
Ability Pharmaceuticals	Aliath Bioventures	Aptadel Therapeutics
Abingworth	Alira Health	Araclon Biotech
Abliva	Alkapharmics	ARCH Venture Partners
Accure Therapeutics	Ally Bridge Group	Arecor Therapeutics
ACM Biolabs	Alpha Wave Global	argenx
Acousia Therapeutics	ALSA Management Services	Ariceum Therapeutics
Actigen	ALSA Ventures	Arthex Biotech
AdBio Partners	Altitude Life Science Ventures	Asabys Partners
Adcendo	AlveoGene	Asahi Kasei Pharma
Addex Therapeutics	Alveus Therapeutics	AseBio - Spanish Bioindustry Association
Adiposs	Amarna Therapeutics	Asociación Centro de Investigación Coop- erativa
Adva Biotechnology	Amgen	Astherna
Advanced Clinical	AM-Pharma	AstriVax
Advent Life Sciences	Ampleia	Atamyo Therapeutics
Aeon 5	Amyl Therapeutics	Atar Advisors
Agency for Science, Technology and Re- search (A*STAR)	Ananda Immunotherapies	Atopia Therapeutics
Agio Capital &	Anaveon	
		Atriva Thera-



2023 highlights

 <p>MORE THAN 290 VCs</p> <p><i>from European, U.S. and Asian firms</i></p>	 <p>MORE THAN 600 BIOPHARMA EXECUTIVES</p> <p><i>including 330 CEOs + 150 CFO/CBO/COOs</i></p>	 <p>MORE THAN 170 PRESENTING COMPANIES,</p> <p><i>including 104 'Next Wave' newcos</i></p>
---	--	--



peutics	Brandon BioCatalyst	Criteria Bio Ventures
Augustine Therapeutics	Brandon Capital	Crossfire Oncology
AUM Biosciences	British Patient Capital	CTI Life Sciences Fund
Avant Bio	Broadview Ventures	Cumulus Oncology
Azafaros	Butterfly Medical	Curadh MTR
B7 Therapeutics	Caedo Oncology	CurE-me
Back Bay Life Science Advisors	Calida Therapeutics	Curve Therapeutics
Baker McKenzie	Calliditas Therapeutics	Cymba
Bantam Pharmaceutical	Calluna Pharma	Cytoki Pharma
Barclays	Cambridge Innovation Capital	Cyxone
Belfius Bank	Cancer Research Horizons	Dania Therapeutics
BioArctic	Candel Therapeutics	Dawn Biopharma
Biobide (BBD Biophenix L.S.U)	Capital Grand Est	Deep Science Ventures
BioBloC	Captain T Cell	Delin
BioCortex	CARTemis Therapeutics	Delpor
Biofidelity	CaSRevolution	Dermaliq Therapeutics
BioGeneration Ventures (BGV)	CatalYm	Diamyd Medical
Biogipuzkoa Health Research Institute	Catalyst Advisors	Dimericon Therapeutics
BioInnovation Institute Foundation	CBT Advisors	DiNAQOR
BioInvent International	CD3-KULeuven	Diputación Foral de Gipuzkoa
BioMarin Pharmaceutical	CDR-Life	Disco Pharmaceuticals
BiomeBank	Cellaion	Domain Therapeutics
BioNTech	cellvie	Dorian Therapeutics
Bioqube Ventures	Cereno Scientific	Dr. Lang Consulting
Biosaxony Management	Certa Therapeutics	Dr. Reddy's Laboratories
Biotech Austria	Charles River Laboratories	Droia
Biotheus	Chugai Venture Fund	Dualyx
BioVersys	Cilcare	Dunad Therapeutics
Biovision Ventures	Cinference	Dynamic Biosensors
Bioxodes	Circio Holding	Earlybird Venture Capital
bit bio	Citryll	EG 427
BlackRock	Cmr CureDiab Metabolic Research	Egle Therapeutics
Bloodworks	Coave Therapeutics	Eir Ventures Partners
Bloomsbury Genetic Therapies	Columbus Venture Partners	Eli Lilly and Co.
Blue Earth Diagnostics	Commit Biologics	Ellennbe
Blue Wave Therapeutics	Confo Therapeutics	Ena Respiratory
Boehringer Ingelheim Venture Fund	ConvEyXO	Encelta
BOM	Cooley	Engimmune Therapeutics
Bracco Imaging	Coulter Partners	Enhanc3D Genomics
Brainomix	Covington & Burling	EnteroBiotix
Braintale	Crescendo Biologics	Enterome

- Epoqe Pharma

Epsilon

EQT Life Sciences

ESC

EsoBiotec

Esperante Ventures

Ethris

Eurasanté

Euronext

Evariste

EverZom

Evolution Life Science Partners

Evotec

Evox Therapeutics

EXACT Therapeutics

ExeVir Bio

Experimentica

F2G

FCF Fox Corporate Finance

Feldan Bio

Ferring Pharmaceuticals

Fibrocor Therapeutics

FimmCyte

Finnish Drug Discovery Center

Flamingo Therapeutics

Flanders Institute for Biotechnology (VIB)

Flanders Investment & Trade
- Focal Biosciences

Forbion

FoRx Therapeutics

Frazier Life Sciences

FreeMind Group

Fund+

FutuRx

Galimedix Therapeutics

Gate2Brain

Genicity

Gilde Healthcare Partners

Gimv

GlaxoSmithKline (GSK)

GLN-Bio Investments

Global BioAccess Fund

Glox Therapeutics

GlycoEra

GlycoTherapeutics

Golgi Neurosciences

Goodwin

Grey Wolf Therapeutics

Grifols

H.C. Wainwright & Co.

Hadean Ventures

Harness Therapeutics

Hawk Biosystems

HBM Partners
- HealthCap

Healthcare Coalition

HealthCare Royalty

Helicore Biopharma

Hemispherian

High-Tech Gründerfonds Management

HSBC Innovation Bank

Hyloris Pharmaceuticals

i&i Biotech Fund

ICON

ICR Consilium

Iktos

Ilonov

Immunic

Immunis

Immunocoaching Therapeutics

ImmunoScape

ImmuPharma

IMU Biosciences

iN Therapeutics

Indaco Venture Partners

Infinitopes

Inkef


InnoUp Farma

Innovestor Life Science


Inotrem

InSilicoTrials Technologies


INDUSTRY SECTOR



JOB FUNCTION



REGION





Integra Therapeutics	Lundbeckfonden BioCapital	Monument Therapeutics
Invenis Biotherapies	Lundbeckfonden Emerge	Morgan Prestwich Recruitment
Inveready Asset Management	M:M Bio	MP Healthcare Venture Management
Invest in Spain: ICEX	Mabylon	MRM Health
invIOs	Macomics	MSQ Ventures
Invivo Partners	Mapreg	MTS Health Partners
iOnctura	MC Sciences	Multimic Health
Ipsen	MC Services	Muna Therapeutics
IQVia Holdings	MC2 Therapeutics	Myeloma Investment Fund
Jeito Capital	McDermott Will & Emery	myNEO Therapeutics
Jiangsu Hillgene BioPharma	McKinsey & Co.	Myogene Therapeutics
Johnson & Johnson Innovation (JJDC)	McQuade Center for Strategic Research	MyoPax
JP Morgan	MD Anderson	Myriamed
Kali Therapeutics	Medicxi	Myricx Pharma
Karolinska Development	MEDiSTRAVA Consulting	Myrti Biotechnologies
KBio	Medix	NanoCell Therapeutics
Kernal Biologics	Memo Therapeutics	NanoPhoria
Kindred Capital	Merck KGaA	Nerai Bio
King Bioventures	Merck Sharp & Dohme (MSD)	Neumirna Therapeutics
KisoJi Biotechnology	Merck Ventures	NeuVasQ Biotechnologies
Kling Biotherapeutics	Mestag Therapeutics	New Rhein Healthcare Investors
Kudo Biotechnology	MetrioPharm	NH TherAguiX
Kupando	Microbiotica	NLC Health Ventures
Kurma Partners	Microviable Therapeutics	Noema Pharma
Kynos Therapeutics	Midland Pharmaceuticals	Nordic Pharma
La Société Vesalius IV Partners	Mikrobiomik Healthcare Company	NovAliX
Laverock Therapeutics	Milano & Partners	Novelna
Lead Discovery Center	MiNA Therapeutics	Novo Holdings
Leerink Partners	MinervaX	Novo Nordisk
Leyden Labs	Minoryx Therapeutics	Novotech
LifeArc	Mission Therapeutics	NRW.BANK
LifeScience ORG	MitoRx Therapeutics	NUAgo Therapeutics
LifT BioSciences	Mitsui & Co.	Nucleome Therapeutics
Lightstone Ventures	MiWEndo Solution	Nutter McClennan and Fish
LimmaTech Biologics	Modra Pharmaceuticals	Obulytix
LISAvienna	molab.ai	Oculis
Longitude Capital	Monograph	OMass Therapeutics
Luminary Therapeutics	Montis Biosciences	OmicVision Biosciences



Ona Therapeutics	PK Med	RS Oncology
Oncode Accelerator	Pledge Therapeutics	RV Invest
Oncomatrix Biopharma	Pneumagen	Sammy Hofmans
OncoOne Research & Development	Precirix	Sanofi
One Biosciences	Precision BioSearch	Sapient Therapeutics
Oniria Therapeutics	PrecisionLife	Sapreme Technologies
Oost	Pretzel Therapeutics	Scancell Holdings
Optimum Strategic Communications	Private Equity Recruitment (PER)	Scandion Oncology
OrbiMed Advisers	Project Cypress	Scendea
Origenis	PulseSight Therapeutics	Sealantium Medical
Orikine Bio	Pureos Bioventures	Secarna Pharmaceuticals
Orthros Medical	Purespring Therapeutics	Senisca
Osivax	QPMind	Serna Bio
Otsuka Pharmaceutical	Quan Capital	Seroba Life Sciences Management
Outrun Therapeutics	Queen Mary University of London	Sibylla Biotech
Oxford Finance	RA Capital Management	Sidley Austin
Oxford Science Enterprises	Rambam	Silver Arrow
Oxolife	Raya Therapeutic	Simcere Pharmaceutical Group
PamGene	ReBio Pharma	Simmunext Biotherapeutics
Pan Cancer T	Refoxy Pharmaceuticals	Sitala Bio
Panakes Partners	Rejuvenate Biomed	SIX Swiss Exchange
Panmure Gordon	reMYND	SNIPR Biome
Parkinson's Virtual Biotech	Resolution Therapeutics	Sofinnova Partners
PDC*line Pharma	Rewind Therapeutics	SonoThera
PEP-Therapy	Rheacell	Sound Bioventures
Perseo Pharma	Ribometrix	SparingVision
Pfizer	Rinri Therapeutics	Spirea
Pharmacosmos	River BioMedics	SpliceBio
PhoreMost	Rnatics	SPRI
Pioneering Medicines	ROC Venture Group	SR One
Piper Heartland Healthcare Capital	Roche Venture Fund	Stalica

partneringONE® opened April 8, 2024

Update your company and personal profiles within 24 hours of registering and prepare to start scheduling meetings in partneringONE. Don't forget, this year's event includes two bonus days of digital partnering, May 22-23, 2024.

For assistance with partneringONE, please contact:
partneringteam@informaplcn.microsoft.com





Steminov	Tessellate Bio	Vesale Bioscience
StemSight	TetraKit Technologies	Vesper Bio
Step Pharma	Theranica Bio-Electronics	Villus Therapeutics
STipe Therapeutics	Thermo Fisher Scientific	Vilya
Storm Therapeutics	Thermosome	Viralgen Vector Core
StromaCare	Thuja Capital Management	Vivet Therapeutics
Sulis	Tolremo Therapeutics	Vivo Capital
SunRock Biopharma	TPG Biologics	VRG Therapeutics
Sunstone Life Science	Traverse Biotech	Vzarii Therapeutics
Sunstone Life Science Ventures	TreeFrog Therapeutics	WEHI Ventures
SurBio+	Tribune Therapeutics	Wellcome Sanger Institute
SurvivX	Trill Impact	Wellington Management Company
SV Health Investors	Trophic Communications	WMT
Swedish Orphan Biovitrum	Truffle Capital	Xenothera
Syncona Investment Management	Tubulis	XGen Venture
Syndivia	UBS	Yeda Research and Development
Synendos Therapeutics	UCB Biopharma	Ysios Capital Partners
Synklino	UCB Ventures	Zai Lab
SynOx Therapeutics	UK BioIndustry Association	Ziphius Vaccines
Tacalyx	Umlaut.bio	Zyvran Pharmaceutical
Tagworks Pharmaceuticals	Unicycive Therapeutics	
Taiho Ventures	Univercells	
Takeda Ventures	Vaderis Therapeutics	
TauC3 Biologics	Van Lanschot Kempen	
TECregen	VarmX	
Teitur Trophics	VAXDYN	
Telomere Therapeutics	V-Bio Ventures	
TES Pharma	Versant Ventures	
Tesi	Vertex Ventures	

BONUS CONTENT



Join Jeff Cranmer, Executive Editor and host of *“BioCentury This Week,”* for this exclusive “Bio€quity Europe” preview episode:

Week of May 6

Bio€quity Europe Preview

BioCentury This Week features in-depth conversations with BioCentury’s editorial team on current topics in biopharma. Available on Apple, Spotify, YouTube or your podcast channel of choice.

PRELIMINARY AGENDA

**subject to change*

SATURDAY, MAY 11, 2024

Recommended arrival into San Sebastián, Spain.
[CLICK HERE TO VIEW THE OFFICIAL BIO€QUITY EUROPE TRAVEL GUIDE](#)

SUNDAY, MAY 12, 2024

11:00 AM – 4:00 PM

PRE-EVENT NETWORKING EXCURSIONS

**Space is limited, please register in advance.*

- Pintxos Walking Tour
- Txakoli Winery Tour
- 9-hole Golf Scramble
- Chillida Leku Museum Tour

5:30 PM – 6:30 PM

REGISTRATION & NETWORKING

**Join us at the San Telmo Museum for our 2024 Welcome Reception & 4th BioCentury “Scene Setter” opening plenary.*



6:30 PM – 7:30 PM

BIOCENTURY’S 4TH SCENE SETTER PANEL

Continuing a long Bio€quity Europe tradition, BioCentury’s Scene Setter panel will set the stage for this year’s conference, featuring some of Europe’s leading investors and biotechs, in a dynamic conversation that engages the audience and highlights this year’s theme: rising above the noise.

Session Chair:

Simone Fishburn, Ph.D., VP and Editor in Chief, BioCentury

Panelist:

Maina Bhaman, Partner, Sofinnova Partners
Hakan Goker, Ph.D., Managing Director & Head, M Ventures
Susan Hill, Ph.D., CEO, Mestag Therapeutics
Joël Jean-Mairet, Ph.D., Managing Partner, Ysios Capital
David Ke, Managing Director, J.P. Morgan
Vanessa King, Ph.D., Biotech CEO, Founder and Board Member

7:30 PM – 8:30 PM

NIGHT CAP COCKTAIL NETWORKING RECEPTION



MONDAY, MAY 13, 2024

7:30 AM – 8:30 AM

NETWORKING BREAKFAST

FIRESIDE CHAT: VOICES, VALUES AND VENTURE LESSONS IN LEADERSHIP

Kate Bingham is not only one of biotech's most prominent female investors, but one of the few leaders in the industry to become a household name, having led the U.K.'s vaccine taskforce during the pandemic and steered its highly successful COVID-19 vaccine program. As managing partner of SV Health Investors she has created numerous companies, and pioneered the launch of the Dementia Discovery Fund. In this Fireside Chat, Bingham will discuss the drivers of successful leadership, how to walk the tightrope of diplomacy and effective management, and what she hopes to see in the next generation of VC investors.

Session Chair: Simone Fishburn, VP & Editor in Chief, BioCentury

Emcees: Rabab Nasrallah, Ph.D., Principal, Earlybird Venture Capital, and Member, Breaking 7%

Paula Olazábal, Partner, Ysios Capital and Member, Level 20 Spain Committee

Panelist: Kate Bingham, Managing Partner, SV Health Investors

8:00 AM – 9:00 AM

REGISTRATION & NETWORKING BREAKFAST *at the Convention Center

8:40 AM – 8:45 AM

OPENING BELL CEREMONY

Hosted by: Euronext Paris S.A.

Susana de Antonio, Head of Listing Euronext Brussels

Sophie Stegen, Head of Listing Euronext Spain

8:45 AM – 9:00 AM

WELCOME TO BIO€QUITY EUROPE 2024

Join BioCentury, EBD Group, and the San Sebastián Regional Hosts to celebrate the official opening of the 24th Bio€quity Europe.

David Flores, President & CEO, BioCentury

Ane Insausti, Deputy of Economic Development and Strategic Projects, Gipuzkoa

Joël Jean-Mairet, Ph.D., Managing Partner, Ysios Capital

Claire Macht, Director, European Portfolio, EBD Group

Arantza Tapia, Minister for Economic Development, Sustainability and the Environment

9:00 AM – 7:00 PM

C-LEVEL PARTNERING MEETINGS

9:00 AM – 9:45 AM

CONFERENCE REPORT KEYNOTE: HOW TO RISE ABOVE THE NOISE

Recent successful IPOs, business development and M&A activities have boosted optimism in the biotech community. Yet, an increasing number of biotechs are competing for available wallets and partnership opportunities. How can biotechs successfully differentiate and 'rise above the noise'? And how can investors and business development teams deploy their capital efficiently, identifying future 'winners' early? Insights Partner McKinsey & Company debuts its fifth annual report on European biotech, with an analysis of key trends in the biotech investment landscape (the 'noise'), and a study of companies that have risen above the noise with a deep dive on a selection of European hubs. Advanced access to McKinsey's 2024 Biotech Report will be available exclusively to all Bio€quity delegates.

Session Co-Chairs: Alexandra Zemp, Ph.D., Partner, McKinsey & Company

Joseph Lydon, Partner, McKinsey & Company



9:45 AM – 10:45 AM

TALENT SHOWCASE: IS YOUR BOARD RISING ABOVE THE NOISE?

Good boards will not simply make noise, they'll help their companies rise above the noise. But that takes the right combination of skills, perspectives and personalities. Embracing diversity of thought and experience means making time and room for discussion, but efficiency of decision-making is paramount for companies under pressure. This panel will discuss how to assemble, manage, and adapt the right board to help companies differentiate and manage through a challenging era.

Session Chair: Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury

Panelists: Roel Bulthuis, Managing Partner, Syncona Investment Management

Bianca Coulter, CEO, Coulter Partners

Rachel Mears, Partner, Jeito Capital

Fiona MacLaughlin, Ph.D., Senior Director, Venture Investments, Johnson & Johnson Development Corporation (JJDC)

Catherine Pickering, Ph.D., Director & CEO, iOnctura

Naveed Siddiqi, M.D., Senior Partner, Novo Holdings

10:00 AM – 6:00 PM

PRESENTING COMPANY ROADSHOW TRACKS

10:45 AM – 11:15 AM

MORNING NETWORKING BREAK

11:15 AM – 12:00 PM

CONCURRENT SESSIONS

SESSION 1:

R&D SHOWCASE #1: SCALING UP EUROPE'S ACADEMIC ENGINE IN CELL AND GENE THERAPY

In the world of cell and gene therapies, strong, early clinical data from small academic studies have repeatedly catalyzed paradigm shifts that reverberate across industry. European physician-scientists have been at the forefront of several breakthroughs, including CAR T cells for autoimmunity. But is that transformational value being captured by local ecosystems? What is the playbook for fostering and commercializing the translational leaps by Europe's academic KOLs?

Session Chair: Karen Tkach Tuzman, Ph.D., Director, Biopharma Intelligence

Panelists: Jean Philippe Combal, CEO, Vivet Therapeutics

Mark Kotter, Founder and CEO, bit bio

Dima Kuzmin, Managing Partner, 4BIO Capital

Elisa Petris, Lead Partner, Syncona Investment Management

Jimmy Vanhove, CEO, Viralgen

Miquel Vila-Perelló, CEO, Splice Bio

SESSION 2:

PREPARING FOR THE SEA CHANGE IN EUROPEAN PHARMA LEGISLATION

Europe is undergoing the biggest remaking of its pharmaceutical legislation in a generation, which will influence how investors and companies think about the European commercial market. This expert panel will describe the potential impact on biopharma companies, and identify ways the industry can shape the direction of the legislation as it moves through the political process.

Session Chair: Josefine Sommer, Partner, Sidley

Panelists: Caroline Gaynor, Partner, Lightstone Ventures

Sebastian Kreuz, Ph.D., Executive Director, Boehringer Ingelheim Venture Fund

Philip Schwab, Ph.D., Senior Director, Government Affairs, Region Europe, AbbVie

Erik van den Berg, CEO, Memo Therapeutics



12:00 PM – 12:45 PM

CONCURRENT SESSIONS

SESSION 1:

R&D SHOWCASE #2: DERISKING DEMENTIA

From multi-omics to clinical phenotyping, rising above the noise in neuroscience means derisking therapies with human data, deploying biomarkers and carefully matching targets to therapeutic modalities. With drug development for dementia picking up steam, this panel will discuss what it takes to balance risk and opportunity across these parameters to create a product profile that stands out from the pack.

Session Chair: Arno de Wilde, Ph.D., Director, EQT Life Sciences

Panelists: Rita Balice-Gordon, Ph.D., CEO, Muna Therapeutics
 Laurence Barker, Ph.D., Partner, SV Health Investors, Dementia Discovery Fund
 Paulo Fontoura, M.D., Ph.D., Global Head and SVP, Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Roche
 Chiara Liberati, Managing Director, Golgi Neurosciences
 Paul Little, Ph.D., CEO, Vesper Bio

SESSION 2:

BUILDING SUCCESSFUL SYNDICATES

As biotech CEOs look to rise above the noise, building a winning investor syndicate is essential. Deep pockets are important, but investors also must align around capital requirements, key de-risking steps, and continued insider support for the next financing round. In Europe, where syndicates are generally smaller, the need for alignment is more acute. This workshop brings together VCs, institutional investors and board directors to share lessons learned for syndicate success.

Session Chair: Stephen Hansen, Director of Biopharma Intelligence, BioCentury

Panelists: Claire Brown, Ph.D., Partner, Oxford Science Enterprises
 Jason Hafler, Ph.D., Managing Director, Sanofi Ventures
 Andrew Lam, PharmD., Managing Director, Head of Biotech, Ally Bridge
 Greg Parekh, Ph.D., Managing Partner, New Rhein Healthcare
 Christina Takke, Managing Partner, V-Bio Ventures

12:45 PM – 2:00 PM

NETWORKING LUNCH

A Quick & Easy lunch will be available with service beginning at 12:00pm and running until 2:00pm.

2:00 PM – 2:45 PM

CONCURRENT SESSIONS

SESSION 1:

13TH CEO BOOT CAMP: COMMUNICATE, COMMUNICATE, COMMUNICATE

Competition for capital and partnerships is fierce. Communicating your value proposition and how you are differentiated must be Job 1 for the biotech C-suite. Are Europe's biotech leaders succeeding in this crowded environment? BioEquity's annual CEO boot camp lays out what European chief executives must do to stand out against their international competitors.

Session Chair: Carole Nuechterlein, Head, Roche Venture Fund

Panelists: Emmanuel Lacroix, CEO, NeuVasQ Biotechnologies
 Lauren Mifflin, Ph.D., VP, Company Creation, Frazier Healthcare
 Søren Møller, Ph.D., Managing Partner, Novo Seeds
 Mitchell Mutz, Ph.D., Entrepreneur Partner, Vivo Capital
 Bobby Soni Ph.D., Chief Business Officer, BioInnovation Institute



SESSION 2:

DEALMAKERS SHOWCASE: HOW TO GRAB THE ATTENTION OF PHARMA BD&L EXECS

With patent cliffs fast approaching, pharmas and big biotechs are on the hunt for assets to shore up their near-term revenues as well as their longer-term pipelines. At the same time, the big players are inundated with pitches from small biotechs trying to attract a flagship partner. This panel focuses on what biotechs must do to rise above the noise to attract their attention.

Session Chair: Arthur Franken, General Partner, Gilde Healthcare

Panelists: Khatereh Ahmadi, Ph.D., Head of Search and Evaluation, BD&L, Europe and Middle East, MSD

Nerida Scott, Ph.D., Regional Head, EMEA, Johnson & Johnson Innovation

Paul Peter Tak, M.D., Ph.D., President & CEO, Candel Therapeutics

Nathalie Ter Wengel, M.D., European Lead, Worldwide Business Development, Pfizer

2:45 PM – 3:30 PM

CONCURRENT SESSIONS

SESSION 1:

FINANCING TECHBIO – CONVERGING TECH AND BIO TO POWER BIOTECH INTO THE ERA OF AI

There's no "If" anymore, it's all "when" -- everyone now has an AI or machine learning story in biotech, but there's still a lot of noise to know where the value lies. And as technologies emerge that can drive radical improvements, new investment models will be needed to convert them into viable companies. Some traditional tech and biotech VCs are coming together to syndicate, others are building funds or firms from the ground up. This panel will discuss the paths to value creation as biotech enters the era of AI.

Session Chair: Selina Koch, Ph.D., Executive Editor, BioCentury

Panelists: John Cassidy, General Partner, Kindred Capital

Florent Gros, Partner, EarlyBird Venture Capital

Edward Kliphuis, Partner, Sofinnova Partners

Jennifer McMahon, Partner, Seroba

Michael Meyers, Vice Chairman & Head of M&A and Strategic Advisory Services, H.C. Wainwright

SESSION 2:

7TH WEST-EAST ROUNDTABLE: WHAT'S NEEDED TO GROW CROSS-BORDER DEAL FLOW

The surge in East-West dealmaking has shown Asia can be a player in global innovation networks. The challenge is to create more visibility for Asian assets that are not yet on the radar in Europe and the U.S., and for potential partners to access the Asia-Pacific markets. In Bio€quity's seventh West-East Roundtable, dealmakers from both sides will identify what will be needed to maintain deal flow in both directions.

Session Chair: Josh Berlin, Head of Corporate Alliances and Business Development, BioCentury

Panelists: Vishal Doshi, CEO, AUM BioSciences

Frank Kalkbrenner, Ph.D., Global Head, Boehringer Ingelheim Venture Fund

Franck Le Deu, Senior Partner & Co-Leader of Asia Life Sciences Practice, McKinsey & Company

Marietta Wu, M.D., Ph.D., Managing Director, Quan Capital

Shanshan Xu, Ph.D., VP, External Innovations, BioNTech

Echo Hindle Yang, CEO, MSQ Ventures

3:30 PM – 4:00 PM

AFTERNOON NETWORKING BREAK



4:00 PM – 5:15 PM

REGIONAL HOST SESSION: SPOTLIGHT ON SPANISH BIOTECH

PART 1:

CEO PERSPECTIVES: VENTURE CAPITAL AS A GROWTH DRIVER FOR SPAIN'S LIFE SCIENCES SECTOR

Spain's standing in the life sciences has risen over the past decade-plus as its high quality of science offers promise for biomedical solutions, but it's taken time to create companies and attract specialized investors. In this session, local leaders discuss the evolution of the ecosystem, the challenges ahead, and how to attract international VCs to Spain.

Emcee: Alberto Sanz Serrano, Director, Finance & Investor Relations, Invest in Spain

Session Chair: Ion Arocena, CEO, Asebio

Panelists: Joan Perelló Bestard, Ph.D., CEO, Sanifit
Valerie Vanhooren, Ph.D., Co-Founder & CEO, Ona Therapeutics

PART 2:

THE LIFE SCIENCES REVOLUTION IN GIPUZKOA: WHAT'S NEXT?

With a longstanding industrial heritage, the province of Gipuzkoa has emerged as a growing player in the Spanish life sciences ecosystem. This panel will discuss how life sciences in Gipuzkoa can become a driver of the local economy, backed by a local government committed to making the sector attractive to international investors and human talent.

Session Chair: Paula Olazabal, Partner & Head of ESG, Ysios Capital

Panelists: Javier García, Chairman, Viralgen
Ane Insausti, Deputy of Economic Development and Strategic Projects, Gipuzkoa
Arantza Muriana, Co-Founder, R&D Director & CEO of USA, Biobide
Cristina Oyon, Director, Technology, Innovation and Sustainability, SPRI
(The Basque Business Development Agency)
Jorge Presa, CEO, Cyber Surgery

5:15 PM – 6:15 PM

FIRESIDE HAPPY HOUR CHAT

Mike White, head of life sciences for HSBC Innovation Banking, joins BioCentury VP & Editor in Chief Simone Fishburn in a discussion about the state of European biotech, opportunities for alternative financing, including venture debt, and where HSBC is heading after its £1 white night buyout of Silicon Valley Bank UK.

Emcee: Alexander Demoulin, Associate, Bioqube Ventures
Jessica Vitos, Ph.D., Senior Manager, Innovation, Grifols, and Board Member, YVC Collective

Session Chair: Simone Fishburn, Ph.D., VP and Editor in Chief, BioCentury

Panelist: Michael White, Market Manager & Head of Life Sciences, EMEA, HSBC Innovation Bank

7:00 PM – 10:30 PM

NETWORKING RECEPTION - MIRAMAR PALACE

Join BioCentury, EBD Group, and the BioEquity Europe 2024 Regional Hosts for an evening of local food, wine, and networking at Miramar Palace. Built in 1893 at the request of Queen María Cristina, the palace sits on a hill above La Concha Bay and Santa Clara Island.

6:45 PM – Bus departures from the Convention Center

7:00 PM – Networking Reception

*Miramar Palace is conveniently a 30-minute walk along the beach from the convention center, making it easily accessible by foot. If you opt to walk, [click here for directions](#).





TUESDAY, MAY 14, 2024

7:30 AM – 8:30 AM

3RD ANNUAL FUN RUN

*****Departing from the Convention Center***

Rise and shine early and join industry colleagues on a guided fun run through San Sebastián. All levels welcome. Sponsored by the "BioCentury This Week" podcast -- Take BioCentury on the run.

Team Captains: Arthur Franken, General Partner, Gilde Healthcare
Erica Whittaker, Ph.D., VP & Head, UCB Ventures

[Click here to pre-register for the Fun Run.](#)

8:00 AM – 5:00 PM

C-LEVEL PARTNERING MEETINGS

8:00 AM – 9:30 AM

REGISTRATION & NETWORKING BREAKFAST

8:30 AM – 9:30 AM

NETWORKING BREAKFAST:

NAVIGATING VALUE CREATION: REALISING YOUR ASSET'S POTENTIAL ALONG THE CLINICAL DEVELOPMENT PLAN

With M&A continuing to drive investment in the biopharma space, optimizing the right time to exit is essential for rising above the noise. What are the key catalysts and what kind of data will maximally influence an asset's value and determine the scale of value inflection across the clinical development plan? This panel of VCs and biotech CEOs will discuss the implications of alternative exit plans and strategies when seeking investment and debate the impact on the value and risk associated with asset valuation in current deal-making scenarios.

Session Chair: Michelle Morgan, VP, IQVIA

Panelists: Agnès Arbat, M.D., Founder & CEO OXOLIFE
Susan Hill, Ph.D. Biotech CEO, Mestag Therapeutics
Kinam Hong, M.D., Partner, Sofinnova Partners
Joe Hopcraft, Senior Client Partner, IQVIA
Max Klement, Ph.D., Principal Venture Investments, Novo Holdings

9:00 AM – 3:00 PM

PRESENTING COMPANY ROADSHOW TRACKS

9:30 AM – 10:15 AM

CAPITAL MARKETS SHOWCASE: GETTING ATTENTION IN A BUYERS' MARKET

As biotech progresses toward a market recovery, investors are looking for new opportunities. But hundreds of public and private companies are urgently looking to raise new capital after the long bear market, and the reality is that many will not be chosen. This investor-led session will identify the boxes that biotechs much check to attract investor attention in a buyers' market.

Session Chair: Erica Whittaker, Ph.D., VP & Head, UCB Ventures

Panelists: Niles Kumar, Ph.D., Wellington Management
Giovanni Mariggi, Ph.D., Co-Founder & Partner, Medicxi
Ryan Martin, Senior Associate, Oxford Finance
Ksenija Pavletic, Partner, Jeito Capital
Sophie Stegen, Head of Listing Belgium, Euronext N.V.
Anamaria Sudarov, Ph.D., Managing Director, MTS Health Partners



10:15 AM – 11:00 AM

CONCURRENT SESSIONS

SESSION 1:

R&D SHOWCASE #3 - SUCCESSFUL FUNDING FOR PRECISION MEDICINE PRODUCT DEVELOPMENT

The promise of precision medicine – therapies tailored to individuals – has made the most headway in oncology and rare diseases, where it has included advanced therapeutic technologies such as cell and gene therapies. Rapid innovations in medical genetics are expanding those opportunities at a dizzying speed, but putting the pieces in place to turn ideas into action remains a challenge. This session will provide insight into successful approaches for funding of new precision medicines from experienced venture capitalists, biotech CEOs, and pharmaceutical executives.

Session Chair: William Maier, Ph.D., VP & Head, Center for Rare Disease, ICON

Panelists: Matt Cooper, Ph.D., Founder & CEO, Sitala Ltd.
 Brian Liu, M.D., Managing Director, Longitude Capital
 Ilise Lombardo, M.D., CEO, Noema Pharma
 Joep Muijers, General Partner, Gilde Healthcare
 Haru Sugino, Ph.D., Global Head, Search and Evaluation, Global Business Development, Otsuka Pharmaceutical

SESSION 2:

CAPITAL MARKETS WORKSHOP: WORKING WITH NEW SOURCES OF CAPITAL

Sovereign wealth, family offices and other non-traditional investors are exploring biopharma as a way to diversify their portfolios and achieve social goals. But the biotech timeline and a preference for direct investment present challenges to both venture funds and emerging companies. This session explores how investor syndicates and biotechs should be building these new relationships.

Session Chair: Stephen Hansen, Director of Biopharma Intelligence, BioCentury

Panelists: Gemma Game, Head, Healthcare Strategy & Senior Portfolio Manager, Norges Bank Investment Management
 Masha Stromme, Ph.D., Co-Chair, PAACS Invest
 Martin Turner, Ph.D., Associate Director, Policy, Public Affairs & Investor Relations, BIA (U.K. BioIndustry Association)
 Nina Rawal, Ph.D., Partner & Co-Head, Impact Ventures, Trill Impact
 Roderick Verhelst, Principal, Bioqube Ventures

11:00 AM – 11:30 AM

MORNING NETWORKING BREAK

11:30 AM – 12:30 PM

CONCURRENT SESSIONS

SESSION 1:

8TH ANNUAL BIO€QUITY EUROPE PRE-SEED SHOWCASE

Bio€quity continues to showcase new ideas. Watch selected pre-seed companies present to distinguished Bio€quity Europe "judges," who provide high-level feedback on each entrepreneur's pitch, business plan and strategy.

Session Chair: Karen Tkach Tuzman, Ph.D., Director, Biopharma Intelligence, BioCentury

Judges: Karen Bernstein, Ph.D., Chairman, BioCentury
 Steven Biesmans, Principal, UCB Ventures
 Jérôme Van Biervliet, Ph.D., Managing Director, VIB
 Kathleen Williams, Ph.D., Partner, Nutter



SESSION 2:

LEARNINGS ON HOW TO RISE ABOVE THE NOISE

In this special breakout session, Insights Partner McKinsey & Company gathers a panel of biotechs, investors and pharma BD to discuss lessons learned from recent success examples – what excites investors and what doesn't? Are there specific success factors for biotechs to differentiate vs peers?

Session Chair: Joseph Lydon, Partner, McKinsey & Company

Panelists: Stéphane Boissel, President and CEO, SparingVision
Matthias Evers, Ph.D., Chief Business Officer, Evotec
Baruch Harris, Ph.D., Chief Operating Officer, Pretzel Therapeutics
Simon Kerry, Ph.D., CEO, Curve Therapeutics Ltd.
Bonnie van Wilgenburg, Principal, Monograph Capital Advisors

12:30 PM – 1:30 PM

NETWORKING LUNCH

1:30 PM – 2:30 PM

CONCURRENT SESSIONS

SESSION 1:

R&D SHOWCASE #4: CAMBRIAN EXPLOSION IN ADCs; WHAT ARE EUROPE'S LEVERS TO RISE ABOVE THE NOISE?

As competition escalates in ADCs, companies are exploring new targets, linkers, payloads and indications, and improving the science behind ADC manufacturing. This panel will discuss what the next generation of ADCs should be, what advantages European players can leverage to draw investors, and how the ADC landscape in Europe will fare against steep competition from the U.S. and Asia.

Session Chair: Karen Tkach Tuzman, P.h.D., Director, Biopharma Intelligence, BioCentury

Panelists: Christoph Broja, Managing Director, EQT Life Sciences
Ingo Lehrke, Chief Business Officer, Tubulis
Michael Pehl, CEO, Adcendo
Jonathan Tobin, Partner, Brandon Capital
Anne Vroon, VP of Business Development at Genmab

SESSION 2:

R&D SHOWCASE #5: HOW WILL EUROPE USE ITS VAST BIOMEDICAL DATA LAKE TO POWER DRUG FINDING AND DRUG DEVELOPMENT?

Europe's integrated healthcare systems and investments in innovative biobanks have created some of the richest biomedical data repositories in the world. The rapid acceleration of AI now promises to turn reams of data into actionable insights. This session will discuss how innovators are reducing AI to practice for target discovery and trial design using Europe's data hubs, and whether signal-finding this way can stand out against a sea of noise in this rapidly moving field.

Session Chair: Selina Koch, Ph.D., Executive Editor, BioCentury

Panelists: Emmanuelle Astoul, Ph.D., Interim Head of Translation, Wellcome Sanger Institute
Rowan Gardner, Co-Founder and Chief Business & Investment Officer, PrecisionLife
Nick Lench, Ph.D., Executive Director, Nucleic Acid Therapy Accelerator



2:30 PM – 3:15 PM

3RD FUTURE LEADERS OF EUROPEAN INVESTMENT

Once again, BioEquity Europe closes by looking ahead. How will the next generation of European financiers rise above the noise? How are they planning to identify, create and build successful innovator companies, and what are they aiming to do differently? In this closing Future Leaders plenary, up-and-coming VCs describe their strategies for raising and deploying capital in Europe.

Session Chair:

Karen Wagner, Ph.D., Managing Partner, Ysios Capital

Panelists:

Gabriela Ecco, Ph.D., Senior Associate, +ND Capital

Anne Grahl, Ph.D., Associate, Pureos Bioventures

Emma Johnson, Investment Manager, British Patient Capital

Therese Liechtenstein, Ph.D., Investment Director, M Ventures

Campbell Stewart M.D., VP, Novo Holdings Venture Investments

3:15 PM – 4:00 PM

CLOSING RECEPTION & HAND-OFF CEREMONY TO 2025 REGIONAL HOSTS

Join BioCentury and EBD Group for a final round of networking as we celebrate the conclusion of BioEquity Europe 2024 in San Sebastián and hand over the reins to the Regional Hosts of BioEquity Europe 2025.

4:30 PM – 10:00 PM

ECOSYSTEM TOUR & RECEPTION **LIMITED CAPACITY, [REQUIRES ADDITIONAL REGISTRATION](#)*

Learn about the biosciences strategy for the territory of Gipuzkoa and Basque Country and meet local leaders in this exclusive tour for BioEquity delegates. Visit BIC Gipuzkoa (the organization responsible for entrepreneurship, incubation, and acceleration of companies, and meet with officials). Afterwards, join the AseBio Investor Day Reception for a final round of networking.

4:30 PM

Buses depart the convention center

4:45 PM – 7:30 PM

Ecosystem Tour

8:00 PM – 10:00 PM

AseBio Investor Day Networking Reception at Aquarium de San Sebastián



Let us help you AND your team members prepare for your 1x1 meetings

Starting April 1, 2024, receive complimentary access to BioCentury's business intelligence platform. Research pipelines, financings, deals and exclusive analysis to help you prepare for BioEquity meetings with potential investors and partners.



Want to learn more?

[Schedule an online session](#)

with BioCentury for tips on how to use BCIQ to prepare for BioEquity Europe, and other industry conferences.



EVENT ORGANIZERS

BIOCENTURY BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. www.biocentury.com

EBD GROUP EBD Group is the leading partnering firm for the global life science industry.

Our mission is to facilitate the critical, strategic connections that drive life science dealmaking.

We specialize in bringing people together, whether face-to-face at one of our leading global life science partnering events powered by partneringONE, or virtually through our online community of dealmakers and thought-leaders. www.ebdgroup.com

INSIGHTS PARTNER

McKinsey & Company McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next. www.mckinsey.com

FOUNDING SPONSOR

Sofinnova partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability.

Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders

around the globe. Today, Sofinnova Partners has over €2.5 billion under management. www.sofinnovapartners.com

REGIONAL HOST COMMITTEE



Gipuzkoako
Foru Aldundia
Diputación Foral
de Gipuzkoa

The Provincial Council of Gipuzkoa is responsible for governing and administering the province of Gipuzkoa. Its President is elected by the General Assembly and is

responsible for implementing the programme of the government, which is made up of provincial councillors appointed by the President. The General Assembly is the governing body of the Provincial Council and is responsible for setting the guidelines for and aims of the provincial government's actions. www.gipuzkoa.eus/web/council

YSIOS CAPITAL Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide fostering a positive impact on patients and society. ysioscapital.com

R&D SESSION SPONSOR



ICON is the world's leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical

research providing a comprehensive suite of outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives.

Our outsourcing models can be adapted to suit small local trials to large global programs, including full service, standalone services, FSP and full asset development.

With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 113 locations in 53 countries. www.iconplc.com

WELCOME RECEPTION CO-HOST



HCW
H.C. WAINWRIGHT & CO.

H.C. Wainwright & Co. is a full-service corporate and institutional investment bank dedicated to providing equity, credit and royalty-related capital mar-

kets, mergers and licensing advisory services to our clients, with an emphasis on the life sciences while spanning several other industry sectors. In addition, HCW provides fundamental equity research, sales and trading services in support of our clients.



HCW has been ranked as the leading placement agent for CMPOs, RDOs and PIPEs (in the aggregate) since 1998 (source: Placement Tracker). For more information visit H.C. Wainwright & Co. on at, www.hcwco.com

TALENT SHOWCASE SPONSOR



JJDC is the strategic corporate venture arm of Johnson & Johnson (J&J) and is part of the Johnson & Johnson Innovation (JJI) team. JJDC was established more than 50 years ago and is the longest-running corporate VC firm. We invest in medtech and biotech companies of all stages (NewCo formation, seed, series A and beyond, PIPEs, etc.). We are a committed long-term investor because our success is defined by helping develop innovation that improves patient outcomes. Over the last five decades, JJDC has invested billions of dollars in hundreds of companies and onboarded several into the J&J portfolio. jininnovation.com/venture-investing-jjdc/year-in-review

NETWORKING BREAK SPONSOR



We are the leading retained search and recruitment specialists for private markets professionals. We work across investment strategies, in-house functions and geographies. Whether you are building your team or seeking a vital strategic hire, we go to extraordinary lengths to identify and attract exceptional professionals for private equity, venture capital, private credit, secondaries and real assets. Every day we bring people together who will shape the future of this dynamic, international industry. www.per-people.com

PRE-EVENT NETWORKING EXCURSIONS HOSTS



Columbus Venture Partners is a Spanish independent venture capital that brings a unique approach for investing in outstanding early-stage and high growth opportunities in the life science industry of Spain.

Our team includes solid and internationally experienced investment professionals with a deep scientific, medical and business development background combined with a proven experience in building and investing in companies to accelerate their commercialization.

The combination of industry possibilities and investment experience will provide Limited Partner investors in the Fund a level of professionalism and deep expertise that is essential for success in this field. columbusvp.com

PRECISION BIOSEARCH Founded in 2020, Precision BioSearch provides a distinctive personalized service, recruiting top-tier talent for investor-backed, early-stage biotech ventures, from Board to C-suite and VP levels.

Our expertise lies in navigating the competitive landscape of next-generation therapeutics, crafting leadership teams of visionary experts who inspire and drive innovation forward.

Precision BioSearch employs a rigorous, agile methodology to expedite critical hiring, empowering organizations to scale swiftly and confidently. With expert proficiency spanning every stage of the recruitment process, our extensive relationships, networks, and impactful science-led communication consistently yields exceptional outcomes for investors and their portfolio companies. precisionbiosearch.com



OXFORD FINANCE

Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.

Our capital provides clients with the fuel needed for innovation and growth. oxfordfinance.com



Viralgen is a CDMO that supports development through large-scale commercial production of cGMP certified adeno-associated virus (AAV) for cell and gene therapies. Based in San Sebastián, Spain the company operates as an independent subsidiary of AskBio, which is a wholly owned subsidiary of Bayer AG. Viralgen offers the Pro10™ based suspension platform, a technology licensed from AskBio found to increase scalability, performance, and yield of AAV therapies. The company's state-of-the-art facilities include a clinical facility with 250 L and 500 L bioreactors and a commercial facility consisting of three modules, each having three cGMP suites with capacities of >2,000 L. viralgenvc.com

SPONSORS



Ally Bridge Group is a global healthcare manager focused on high-impact life science innovation across private and public markets. Founded in 2013 by Frank Yu, Co-Chief Executive Officer and Co-Chief Investment Officer, the firm manages assets from offices in New York and Hong Kong.

Our mission is to generate superior risk-adjusted returns for investors while seeking to address unmet medical needs. We aim to achieve this by blending deep scientific and clinical research with financial and capital markets expertise. ally-bridge.com



ASEBio, the Spanish Bioindustry Association, brings together and represents the interests of companies, associations, foundations, universities and technology and research centres that work in the field of

biotechnology in Spain.

We collaborate closely with regional, national and European governments, as well as with social organisations that are committed to science and the use of biotechnology to improve people's lives and promote environmental sustainability, economic development and high value-added employment.

Over the past 25 years, we have been working to bring about positive political and economic changes that foster and drive development of the Spanish biotechnology sector. We are committed to the use of biotechnology to improve quality of life and promote environmental sustainability, economic development and qualified jobs. www.asebio.com/en



BII offers entrepreneurially-minded researchers or anyone with a research-based idea help

to bring interdisciplinary ideas to life and research to market. We offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts. Our main focus is health tech, bio-industrials and therapeutics. We envision that strong collaborations, a passion for science, and an open mind will foster research-based innovation and viable start-ups. BII does not work for profit but for the benefit of human welfare and society around the globe. bii.dk



Bioqube Ventures is a specialist life sciences investment firm founded in 2016. The team consists of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth

paths. In 2020, Bioqube Ventures launched the Bioqube Factory Fund I, with a focus on the discovery and development of new therapeutic platforms and assets. With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures will exclusively invest in the most promising innovative science in Europe and beyond.

www.bioqubeventures.com



Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in ground-breaking companies to drive innovation in

biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its

clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF's focus is to target unprecedented concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. www.boehringer-ingelheim-venture.com



Candel is a clinical stage biopharmaceutical company developing multimodal biological immunotherapies to help fight cancer. Candel's two multimodal

biological immunotherapy platforms are based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs. CAN-2409, the lead adenovirus platform product candidate is in phase 2 and phase 3 trials in lung, pancreatic, and prostate cancers. CAN-3110, the lead HSV platform product candidate is in an investigator-sponsored phase 1 trial in recurrent high-grade glioma (HGG). Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for cancer. www.candeltx.com



Coulter Partners provides leadership

consultancy to Life Sciences, Health and Technology innovation businesses globally. We build teams that change the world and create a better future. Over 20 years we have delivered on 1000s of assignments across the USA, Canada, UK/Europe, and APAC, advising companies and investors on how to shape and hire their boards and leadership teams. We strongly impact value and growth. Our 120 experts operate uniquely as one global team. With our track record, AI, bespoke systems and wealth of data, we fuel the ability of investors, boards and executive teams to deliver value from innovation. www.coulterpartners.com



EQT Life Sciences

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare venture capital firm, into

the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. eqtgroup.com



EURONEXT
10 YEARS SINCE IPO

Euronext is the leading pan-European market infrastructure and plays a key role at the heart of Europe's financial markets. We operate regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal, connected via a single trading technology offering access to all financial instruments across our markets. We provide custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal, and clearing through our CCP in Italy. With our unique federal model as a foundation, Euronext is building the leading market infrastructure in Europe to shape capital markets for future generations. euronext.com



Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture & Growth and Private Equity. The Venture & Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics and health tech, based in Europe and North America. For more information, visit the company's website at www.gildehealthcare.com



INVEST IN SPAIN

Invest in Spain is an executive division of ICEX Trade and Investment, a publicly owned business-oriented entity of the Ministry of Economy, Trade and Business's Secretary of State for Commerce. Our mission is:

To promote, attract and consolidate foreign direct investment in Spain, especially focusing on new investment projects in industry, technology and services.

To connect international investors with the Spanish business ecosystem offering personalized and confidential information that facilitates contact between Spanish companies seeking capital and foreign investors.

To position Spain as a global platform for international business and investments and as an internationalized and competitive economy. www.investinspain.org/en/index



Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States.

Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

www.jeito.life



M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany. We invest in Biotechnology and Technology, covering the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.

We invest into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence. www.m-ventures.com



Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs. Medicxi is currently investing out of its most recent early-stage and late-stage funds and, additionally, continues to manage the Index Ventures life sciences portfolio. www.medicxi.com



For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. www.msd-uk.com



MTS Health Partners is a leading healthcare-dedicated investment bank that provides strategic and financial advice to the global healthcare industry. Since 1999, MTS has offered clients strategic and M&A advisory services and equity and structured financing expertise, and has executed 282 transactions representing over \$121 billion of value. In 2023, MTS secured the second-highest total M&A deal value and tied for third in total M&A deal count for biotech acquisitions valued at \$1+ billion, according to BioCentury. www.mtspartners.com



NEW RHEIN
HEALTHCARE INVESTORS

New Rhein Healthcare Investors, headquartered in Philadelphia, PA, is a dynamic life sciences-

focused venture capital fund. Distinguishing itself by applying a private equity business model to venture capital investing, New Rhein strategically targets assets with proven clinical safety and efficacy.

At the core of New Rhein's investment strategy is a commitment to actively manage the value creation process. This involves taking substantial stakes in a select number of companies to enable a concentrated focus on successful product development and commercialization, while mitigating science-based risks.

New Rhein's team is comprised of former senior executives from renowned pharmaceutical companies, who bring industry-specific expertise to each deal. Steering the fund's deal-making, due diligence, and management decisions, their support allows New Rhein to sustainably scale businesses, ensuring the delivery of value to patients, payors, strategic acquirers, and investors. www.newrhein.com

NOVO
holdings
Investors in life science

Novo Holdings is a holding and investment company, responsible for managing the operating and financial assets of the Novo Nordisk Foundation. Headquartered in Copenhagen and wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder in Novo Nordisk and Novozymes and manages an investment portfolio with a long-term return perspective. The Novo Holdings Investment Portfolio is comprised of Life Science Investments and Capital Investments. We aspire to be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact. Novo Holdings operates from offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of \$106 billion.

www.novoholdings.dk

Nutter

Nutter, McClennan & Fish advises biotechnology companies and investors. We provide timely, pragmatic guidance

to strategic buyers looking to capitalize on market opportunities, investors seeking to expand their presence, and companies looking for experienced counsel to guide them through the complexities of a transaction. We have a proven track record of successfully protecting intellectual property assets. We help clients unlock the value of their IP, creating revenue streams from licensing and sales. We also develop IP strategies which determine what innovations should be protected or bolstered and the ones to be licensed or abandoned for optimal return on investment. www.nutter.com

Roche Venture Fund

Connecting Innovation to Value

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients. We make

investments in life science companies aiming to create value by fostering innovation, guiding successful businesses and generating financial return to Roche.

Our commitment to investments is not just about funding - we provide our team's expertise and the promise of long term vision to drive our shared success together.

The Roche Venture Fund invests to develop commercially successful innovative life science companies.

www.roche.com/venturefund.htm

 **SYNCONA**

Syncona's purpose is to invest to extend and enhance human life. It does this by creating, building and

scaling companies to deliver transformational treatments to patients in areas of high unmet need, for the benefit of all our stakeholders. Syncona focuses on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Syncona's balance sheet underpins its strategy, enabling it to take a long-term view as the company looks to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders. www.synconaltd.com

UCB
Ventures

UCB Ventures is an evergreen strategic corporate venture fund established in 2017 to create value from novel insights and technologies that can transform the lives of

patients suffering from severe diseases. We make long term investments in early-stage companies in the US and Europe. We seek breakthrough innovations in next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, and RNA modulation. We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies. www.ucbventures.com



VIB is widely recognized as an established and world-leading knowledge center in life sciences and biotechnology with an excellent reputation in technology transfer. The unique combination of strategic basic research and a clear focus on innovation and business is one of the major contributors to its success. VIB is highly committed to being the driving force behind the growth of the dynamic life sciences clusters in Flanders.

VIB operates in close partnership with the five universities in Flanders – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University. vib.be

SUPPORTING ORGANIZATIONS



B7% Europe

Breaking 7% is a networking group for women in Healthcare investment and BD deal-making roles. The representation of women in GP roles within the industry has ranged between 5% and 12% over the last decade. Originally

established in the US, Breaking 7% aims to build stronger connections between women across the industry and promote professional growth. earlybirdhealth.notion.site/breaking-7-europe-2c90640d393b434bab37fa0723cea403



The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation.

Established 33 years ago, BIA is the award-winning trade association with more than 500 members including: Start-ups, biotechnology and innovative life science companies; Pharmaceutical and technological companies; Universities, research centres, tech transfer offices, incubators and accelerators; A wide range of life science service providers: investors, lawyers, IP consultants, IR agencies.

BIA is the key thought leader for the sector – working across a wide range of related issues including policy, finance, science, regulatory, legal and talent on topics including engineering biology and techbio.

We promote an ecosystem that enables innovative life science companies to start and grow successfully and sustainably, and we do this through Influence, Connect, Save. www.bioindustry.org



BIOTECH AUSTRIA is the association of the Austrian biotechnology industry and has set itself the goal of supporting the development of an innovative branch of industry based on modern life sciences. biotechaustria.org



CONSILIUM

We are a global leader in strategic communications and investor relations,

focused on the healthcare sector. Part of ICR, we are experts across all sub-sectors of healthcare and financial markets and our specialist teams in Europe and the US, enhance profile, reputation and perception with key audiences for a wide range of international healthcare companies.

consilium-comms.com



HollandBIO represents and connects the life sciences companies in the Netherlands. Together we work on our future ideal: a society in which biotechnology makes a maximum contribution to health,

sustainability and economic growth.

To ensure that biotech innovations are quickly and widely available, HollandBIO tackles obstacles that stand in the way of the ambitions of the biotech leaders. We go for progress, even when we have to question the status quo.

www.hollandbio.nl/over-hollandbio



As the organization representing the biotechnology industry as per Article 38 of the Industry Development Act of the Korean Ministry of Trade, Industry & Energy, the Korea Biotechnology Industry Organization

strives to enhance links between the many businesses that constitute the biotechnology industry and while acting as a catalyst for further technological development and industrialization.

We hope to vitalize the activities of our individual businesses to gain greater international competitiveness so that we can contribute to further national economic development.

www.koreabio.org



Lingmed Ltd was founded in 2013 in Hong Kong. Currently we have offices in Shanghai, Beijing and Munich. Lingmed promotes intelligence

databases and connects cross border innovations between east and west. www.lingmed.net



As a French biocluster, Lyonbiopole Auvergne-Rhône-Alpes is the gateway to healthcare innovation in Auvergne-Rhône-Alpes, France. It aims

to federate the actors of innovation, to connect and promote them internationally and to support the emergence and development of innovative technologies, products and services to address global healthcare challenges.



In 2024, Lyonbiopole Auvergne-Rhône-Alpes brings together a community of more than 250 members among which world-class leaders, innovative small and medium size companies, research centers and university hospitals. At the center of this ecosystem, Lyonbiopole supports its members' initiatives to imagine the future of medicine and to develop breakthrough healthTech innovation available for tomorrow's patients.

lyonbiopole.com/en



MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients' cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.

msqventures.com



Led by industry leaders, we provide strategic communications support to our clients across the UK, Europe and US. Our team has vast experience of working in the healthcare and life sciences sectors and has advised on numerous cross border transactions, including on the London Stock Exchange, Euronext and NASDAQ.

We have long established partnerships with our network in Sweden, The Netherlands, Switzerland and the US.

www.optimumcomms.com

SIDLEY

Sidley is a global law firm with more than 150 years history and committed to providing excellent client service, fostering a culture of cooperation and mutual respect. Sidley's pioneering Global Life Sciences practice comprises an experienced team of approximately 200 lawyers across numerous legal disciplines in our offices around the world. Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, Sidley team offers clients a holistic legal approach that will smooth the path to navigate industry changes, technological advances, market demands and policy hurdles.

www.sidley.com/en/global/services/life-sciences



SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 300 members.

Sweden has an innovative life science industry, strong academia and world leading infrastructure for research.

Our members are companies active within pharma, biotech, diagnostics and medtech and comprise the entire range from small start-ups, to SMEs and large enterprises. Many are engaged in research and development. Other members are experts in fields such as IP, law, finance, product development, life science communication and business development.

swedenbio.se/information-in-english



YVC collective is a network of emerging life sciences venture capital (VC) players. We create events and meet-ups for YVCs to promote a closer connection between professionals in the life science VC industry in Europe. Our different events aim to drive career development and foster collaboration and knowledge exchange. yvc-collective.com

THE BIOCENTURY SHOW

Tune in to BioCentury's twice-monthly interview series with industry leaders who are advancing the future of medicine. Available for free via webcast or podcast.

Recent guests include:

- **Robert Nelsen**, Managing Director, Arch Venture Partners
- **Khoo Shih**, Ph.D., ClavystBio
- **Simeon George**, M.D., CEO & Managing Partner, SR One
- **Fiona Marshall**, Ph.D., President, Novartis Bio-medical Research
- **Gil Bar-Nahum**, Ph.D., Managing Director, Jefferies International

To View Recent Episodes,
Visit: BioCenturyYouTube.com





REGISTER ONLINE — WWW.BIOEQUITYEUROPE.COM

VISA INFORMATION:

For visa requirements, please visit the [website of the responsible Spanish ministry](#).

Should you require an invitation letter for your visa application, please email EBDbilling@informa.com with the information below, and they will be happy to issue the letter for you.


Full Name as shown on passport

Passport Number

Date of Issue

Date of Expiry

Date of Birth



OFFICIAL TRAVEL GUIDE:

[Click here to download the official Bio€quity Europe 2024 Travel Guide.](#)



REGISTRATION / PRICING SCHEDULE

- **All Access Pass: €2885 + 21% VAT**
book by April 2 and save €300
- **All Access Service Provider: €3450 + 21% VAT**
book by April 2 and save €250
- **Digital Access Pass: €2095**
- **Full Presenting Company Slots: €5250**
book by April 2 and save €500
- **Presenting Company Poster Spotlight Add On: €695**

GROUP DISCOUNT PRICING:

Discounts are available for groups of five (5) or more from any one company. For additional information and pricing, please email:

bioequityhelp@biocentury.com

Bio€quity Europe 2024 will take place at the:

Kursaal Elkargunea Center

Zurriola Hiribidea, 1
20002 Donostia - San Sebastián

To book accommodations at a conference-affiliated hotel, please visit our Hotel & Travel page at: <https://conferences.biocentury.com/bioequity-europe-2024/hotel-and-travel>